Skip to main content
SpringerLink
Log in

Nutzen von SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten bei Menschen ohne Diabetes

Indikationen von Antidiabetika jenseits der Glukosekontrolle

Indications of antidiabetic drugs beyond glucose control

  • FB_CME
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Mod. nach [9, 10, 11, 12, 13, 23, 24, 28]

Literatur

  1. Skyler JS et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298-304

  2. DeFronzo RA et al. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017; 13: 11-26

  3. Baker WL et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275

  4. Packer M. SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action. Diabetes Care 2020; 43: 508-511

  5. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128

  6. McGuire DK et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2021; 6: 148-158

  7. Wanner C et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation 2018; 137: 119-129

  8. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726

  9. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008

  10. Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424

  11. Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385: 1451-1461

  12. Solomon SD et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387: 1089-1098

  13. Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446

  14. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127

  15. Thiele K et al. Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Fail 2022; 9: 2233-2238

  16. Thiele K et al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes Obes Metab 2021; 23: 2814-2818

  17. Voors AA et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022; 28: 568-574

  18. Mann PA, Lehrke M. Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition? J Thorac Cardiovasc Surg 2022; 164: 895-899

  19. Muller TD et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019; 30: 72-130

  20. Cosentino F et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323

  21. Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653-662

  22. Shi Q et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022; 399: 259-269

  23. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22

  24. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384: 989-1002

  25. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA 2021; 325: 1403-1413

  26. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021; 325: 1414-1425

  27. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022; 327: 138-150

  28. Ryan DH et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-69

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum Aachen, RWTH Aachen, Aachen, Deutschland

    Niels-Ulrik Korbinian Hartmann &  Michael Lehrke (Stellvertretender Klinikdirektor)

Authors
  1. Niels-Ulrik Korbinian Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Lehrke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Lehrke.

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: N.-U. Hartmann: keine. M. Lehrke gibt wissenschaftliche Unterstützung durch Boehringer Ingelheim, MSD und Novo Nordisk an, Vortragstätigkeit für Abiomed, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Sanofi und Daiichi Sankyo sowie Beratertätigkeit für Amgen, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk und Sanofi.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten bestätigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hartmann, NU., Lehrke, M. Indikationen von Antidiabetika jenseits der Glukosekontrolle. MMW - Fortschritte der Medizin 165, 42–49 (2023). https://doi.org/10.1007/s15006-023-2343-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-023-2343-z

Keywords:

Search

Navigation